A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients

AIDS

Volumn 27, Issue 5, 2013, Pages 761-768

  Bouazza, Naïm ^a,b   Tréluyer, Jean Marc ^a,b,c,d   Msellati, Philippe ^e   Van De Perre, Philippe ^c,f,g   Diagbouga, Serge ^h   Nacro, Boubacar ⁱ   Hien, Hervé ^h   Zoure, Emmanuelle ⁱ   Rouet, François ^h   Ouiminga, Adama ^h   Blanche, Stephane ^a,c,j   Hirt, Déborah ^a,b   Urien, Saik ^a,b,c  

^a Paris Descartes University   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

^d Université Paris Descartes ^*  (France)

^e INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^f UNIV MONTPELLIER   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

^h CENTRE MURAZ   (Burkina Faso)

ⁱ Service de Pédiatrie   (Brunei Darussalam)

^j Unite d'Immunol Transfusionelle   (France)

more..

Author keywords

Children; Dynamic model; HIV; Population pharmacokinetics

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD DISEASE; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VIROLOGIC FAILURE; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; AREA UNDER CURVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MODELS, THEORETICAL; PREDICTIVE VALUE OF TESTS; TREATMENT FAILURE; VIRAL LOAD;

EID: 84876351965     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835caad1     Document Type: Article

References (26)

1. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002; 2:93-102.
2. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS 2003; 17 (Suppl 3):S5-S15.
3. Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, Timite M, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cô te d'Ivoire. AIDS 2004; 18:1905-1913.
4. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999; 18:682-689.
5. Dybul M, Nies-Kraske E, Dewar R, Maldarelli F, Hallahan CW, Daucher M, et al. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis 2004; 189:1974-1982.
6. Ena J, Pasquau F. Once-a-day highly active antiretroviral therapy: A systematic review. Clin Infect Dis 2003; 36:1186-1190.
7. Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, et al. Once-a-day highly active antiretroviral therapy in treatment- naive HIV-1-infected adults in Senegal. AIDS 2003; 17:1017-1022.
8. Lavielle M, Samson A, Karina Fermin A, Mentré F. Maximum likelihood estimation of long-term HIV dynamic models and antiviral response. Biometrics 2011; 67:250-259.
9. Wu H, Huang Y, Acosta EP, Rosenkranz SL, Kuritzkes DR, Eron JJ, et al. Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr 2005; 39:272-283.
10. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
11. Hirt D, Urien S, Olivier M, Peyrière H, Nacro B, Diagbouga S, et al. Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? Antimicrob Agents Chemother 2009; 53:4407-4413.
12. Rouet F, Chaix M-L, Nerrienet E, Ngo-Giang-Huong N, Plantier J-C, Burgard M, et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 2007; 45:380-388.
13. Bouazza N, Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, et al. Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children? Antimicrob Agents Chemother 2010; 54:3280-3286.
14. Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, et al. Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment. Antimicrob Agents Chemother 2009; 53:4399-4406.
15. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982; 16:143-166.
16. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 2005; 49:1020-1038.
17. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582- 1586.
18. Perelson AS, Ribeiro RM. Estimating drug efficacy and viral dynamic parameters: HIV and HCV. Stat Med 2008; 27:4647- 4657.
19. Samson A, Lavielle M, Mentré F. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Comput Stat Data Anal 2006; 51:1562-1574.
20. Samson A, Lavielle M, Mentré F. The SAEM algorithm for group comparison tests in longitudinal data analysis based on nonlinear mixed-effects model. Stat Med 2007; 26:4860- 4875.
21. McKinney RE Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, et al. A randomized study of combined zidovudine- lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr 1998; 133:500-508.
22. Lewis LL, Venzon D, Church J, Farley M, Wheeler S, Keller A, et al. Lamivudine in children with human immunodeficiency virus infection: A phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis 1996; 174:16-25.
23. Yuen GJ, Lou Y, Bumgarner NF, Bishop JP, Smith GA, Otto VR, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2003; 48:176-182.
24. Wang LH, Chittick GE, McDowell JA. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother 1999; 43:1708- 1715.
25. Srinivas NR, Knupp CA, Batteiger B, Smith RA, Barbhaiya RH. A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients. Br J Clin Pharmacol 1996; 41:207-215.
26. Cimoch PJ, Lavelle J, Pollard R, Griffy KG, Wong R, Tarnowski TL, et al. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:227-234.